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Abstract
Background: In addition to the activation of hepatic stellate cells TGF-β govern apoptosis and
growth control of hepatocytes in liver injury. In non-parenchymal cells, TGF-β induces plasminogen
activator inhibitor 1 (PAI-1) and connective tissue growth factor (CTGF) expression, which are
involved in extra cellular matrix formation. Both genes were also regulated by glucocorticoids,
which in certain cases showed antagonistic effects to the TGF-β-Smad 3 pathway. The purpose of
our work was to investigate the influence of TGF-β and dexamethasone on PAI-1 and CTGF
expression and secretion in primary hepatocytes.
Results: By examining PAI-1 and CTGF mRNA and protein expression in cell lysates and cell-
conditioned media under the influence of TGF-β and dexamethasone, we analysed signalling
pathways controlling their expression. TGF-β and dexamethasone significantly co-induce PAI-1 and
CTGF protein expression. On the other hand, we showed that TGF-β diminished a glucocorticoid
receptor dependent luciferase reporter signal in Hep-G2. Inhibition of Erk downstream activation
decreased TGF-β induced CTGF and PAI-1 expression to a basal level. PAI-1 was directly secreted
by hepatocytes, whereas secretion of CTGF was retarded.
Conclusion: The data provide evidence that beside the TGF-β-Smad 3 pathway CTGF and PAI-1
expression is additionally dependent on Erk activity in hepatocytes giving new insights into
regulation of the profibrogenic proteins.
Background
Hepatocytes fulfil several complex functions, which are
regulated by a fine network of transcriptional regulators.
Particularly glucocorticoids govern crucial functions in
hepatocytes such as glucose metabolism, cell proliferation
and differentiation. Once bound to their cytoplasmic
receptors (GR) the glucocorticoid-receptor-complex is
translocated to the nucleus and binds after dimerization
to a cis-active response element to regulate target genes
[1,2]. Additionally, ligand-bound GR can interact DNA-
independently with transcription factors such as AP-1 or
NFκB, resulting in anti-inflammatory effects [3]. These
properties were pharmaceutically utilised [4]. In liver
injury, the fibrogenetic master cytokine TGF-β activates
hepatic stellate cells (HSC) and induces them to produce
extra cellular matrix (ECM). Further, TGF-β severely
impaired viability and function of hepatocytes [5]. For
this, active TGF-β binds and phosphorylates transmem-
brane receptors with a serine-threonine kinase activity,
which in turn propagates the signal via Smads to the
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ments [6-8].
PAI-1, a member of the serpin superfamily, is regulated by
many different factors among which TGF-β and corticos-
teroids are important one [9,10]. In HSC, TGF-β induc-
tion of PAI-1 leads to an inhibition of protease-dependent
fibrinolytic activity and ECM accumulation [11]. CTGF, a
CCN family protein and also a TGF-β target gene, is
described as a down-stream modulator of profibrotic
TGF-β effects, e.g. in activating HSC and promoting the
deposition of ECM [12-16]. CTGF inhibition is reported
to suppress liver fibrosis in rats by inhibiting HSC-activa-
tion [17]. Both PAI-1 and CTGF are inducible by glucocor-
ticoids [18-20]. Previous studies showed that
glucocorticoids decrease TGF-β-sensitive reporter signal-
ling in primary HSC as well as in CFSC (cirrhotic fat stor-
ing cells) [21,22], but little is known about the effect of
glucocorticoids on endogenous TGF-β target genes in
hepatocytes. Aim of the present study was to characterize
the molecular effects of glucocorticoids on PAI-1 and
CTGF and to ascertain the impact of glucocorticoid-TGF-β
interaction. Therefore, we analysed mRNA and protein
expression of PAI-1 and CTGF by a combined stimulation
with dexamethasone and TGF-β in primary rat hepato-
cytes and found that both proteins are co-induced by TGF-
β and dexamethasone. CTGF as well as PAI-1 expression
control is accomplished by the use of several pathways
and our data indicate that a complex signalling network
regulate the fine tuning of these proteins in hepatocytes.
Results
PAI-1 and CTGF expression after TGF-β dexamethasone 
costimulation
Western blot analysis showed an up-regulation of PAI-1
after TGF-β incubation and a strong enhancement six
hours after a TGF-β-dexamethasone costimulation of
hepatocytes (Fig. 1A, 1B). Whereas no CTGF is detectable
in freshly isolated hepatocytes it is up-regulated by
degrees during cell culture (data not shown). TGF-β-stim-
ulated hepatocytes significantly enhance their CTGF
expression (Fig. 1C, 1D) in a time dependent manner (Fig.
2). Moreover, dexamethasone promotes CTGF expression
in comparison to untreated hepatocytes and a combined
incubation with TGF-β leads to a significant "super induc-
tion" of CTGF.
Direct secretion of PAI-1 and delayed secretion of CTGF by 
hepatocytes
PAI-1 and CTGF contribute for ECM production and dep-
osition. For this purpose they were secreted. Hepatocytes
were treated with TGF-β or TGF-β and dexamethasone and
incubated for 1, 2, and 4 hours, respectively. The time
course of stimulated hepatocytes showed an increasing
amount of PAI-1 in cell lysate and medium after TGF-β
incubation or a TGF-β-dexamethasone cotreatment (Fig.
2). We observed that the PAI-1 export into medium
exceed the PAI-1 concentration of the cell lysate in the
untreated control (Fig. 2, lane 7). A comparison of the
untreated cells depicted a continuous increase of PAI-1 in
medium samples of hepatocytes. In contrast to PAI-1, the
smaller CTGF protein was not observed in notably
amounts in medium samples within a time-frame from 1
to 4 hours, although a time-dependent increase of CTGF
protein in lysates was detected. But after 4 hours the band
intensity of CTGF increased, which was facilitated in those
samples treated with TGF-β (Fig. 1C – 6 h). Additional
experiments showed that only weak CTGF bands were
present in medium samples after stimulations with vari-
ous dexamethasone concentrations (data not shown),
indicating that only TGF-β treated samples triggers CTGF
secretion in hepatocytes.
Life cell observations showed that the combination of
TGF-β and dexamethasone in the used concentrations did
not change cell phenotype. A lactate dehydrogenase deter-
mination of co-treated, single treated or untreated hepato-
cytes averages from 28–33 LDH U/l (37°C), indicating
that no toxic procedures were initiated, which affect cell
integrity.
GR reduces TGF-β signalling and vice versa TGF-β inhibits 
GR signalling in Hep-G2 cells
In previous studies we found that a TGF-β-Smad 3-sensi-
tive reporter construct could be repressed by corticoster-
oids in activated HSC [21]. Additionally, we observed that
TGF-β induced PAI-1 mRNA expression is inhibited by
dexamethasone (data not shown). To check the interac-
tion between dexamethasone and TGF-β-Smad 3 signal-
ling we first transfected Hep-G2 with a (CAGA)9-MLP-luc
plasmid, containing nine Smad-binding elements from
PAI-1 promoter. Our data shows that dexamethasone sup-
presses TGF-β-induced luciferase signal significantly (Fig.
3A). Vice versa transfection studies with a glucocorticoid-
sensitive reporter construct showed that GR transactiva-
tion was clearly inhibited by TGF-β and ectopic Smad 3
(Fig. 3B).
Effects of Erk and JNK inhibitor on CTGF and PAI-1 
expression in hepatocytes
In addition to the Smads, TGF-β is able to signal via Ras-
Mek-Erk pathway and activate the extra cellular signal-reg-
ulated kinases (Erk1 = p44 and Erk2 = p42) and the Jun-
N-terminal kinase (JNK) [23,24]. This settles the question
of whether TGF-β or dexamethasone-induced CTGF or
PAI-1 expression were connected with the Erk- or JNK-
pathway.
Our data demonstrate that TGF-β and TGF-β dexametha-
sone-induced CTGF expression was not affected by inhibi-Page 2 of 9
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Western blot analysis of PAI-1 and CTGF expression in hepatocytesFigure 1
Western blot analysis of PAI-1 and CTGF expression in hepatocytes. Cells were incubated 6 hours with TGF-β, dex-
amethasone or both. Afterwards the hepatocytes were harvested and lysates (40 μg) have been subjected to Western blotting 
and analyzed for PAI-1 and CTGF expression. (A) PAI-1 was significantly induced after co-stimulation with TGF-β and dexame-
thasone, indicating a synergistic effect in hepatocytes. β-actin was assayed as loading control. (B) Densitometric analysis of PAI-
1 expression in hepatocytes and its release into medium. Three independent western blots were analysed; control versus TGF-
β and dexamethasone co-treated cells * p < 0.05; BLU (Boehringer light units). (C) A co-treatment with TGF-β and dexameth-
asone strongly induce CTGF in hepatocytes (PC, day three after plating). A low amount of CTGF could be detected in the 
supernatant of TGF-β stimulated cells. The same blots were analysed for β-actin as loading control. (D) Densitometric analysis 
of three independent experiments. CTGF is induced about 50-fold after a TGF-β-dexamethasone co-stimulation (control ver-
sus TGF-β and dexamethasone co-treated cells * p < 0.005), but it is hardly secreted.
A)
B)
C)
D)
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that dexamethasone strongly dephosphorylates Erk1 and
Erk2, which could be antagonized by mifepristone (data
not shown), whereas TGF-β induced their phosphoryla-
tion. The addition of an Erk inhibitor, a 13 amino-acid
peptide, which selectively prevents interaction between
Mek and Erk and thereby specifically inhibits downstream
Erk activation, reduced TGF-β promoted CTGF and PAI-1
expression (Fig. 4B, 4C). The dexamethasone induced
CTGF expression was not affected by the Erk inhibitor
(Fig. 4A). We ascertain that Erk2 expression level is higher
than Erk1 in three-day old hepatocytes. In contrast to the
Erk inhibitor, an inhibition of JNK-activation had also no
effect on TGF-β-induced PAI-1 expression (data not
shown).
Discussion
It is well established that PAI-1 and CTGF are involved in
the development of liver fibrosis and that they are both
target genes of TGF-β as well as dexamethasone (see syn-
opsis of potential response elements in Table 1). Hence,
this poses the question how their expression and availa-
bility is regulated in hepatocytes.
Multiple pathways are involved in transcriptional regula-
tion of PAI-1 e.g. TGF-β-Smad and TGF-β-MAPK, but not
all mechanisms and interactions are completely under-
stood [17,23-30]. We showed that TGF-β induces PAI-1
expression in primary hepatocytes, which is consistent
with previous findings in HSC and hepatocytes [31,32].
Although dexamethasone antagonized a TGF-β sensitive
Differential secretion of PAI-1 and CTGF in hepatocytesFigu  2
Differential secretion of PAI-1 and CTGF in hepatocytes. Western blot analysis of medium samples, which were col-
lected just before cell lysate was prepared. Hepatocytes were seeded in 90 mm2 petri dishes with a density of 5–6 × 106 cells/
well. Before cytokine and hormone stimulation cells medium was changed (5 ml DMEM without FCS and without phenol red). 
Thereafter, cells were treated and harvested by and by as indicated and 40 μg protein was applied to each lane. After stimula-
tion PAI-1 protein increased during incubation time (1 to 4 h) and was rapidly secreted. CTGF was up-regulated and strong 
expressed in hepatocytes after co-stimulation with TGF-β and dexamethasone. In a time-frame of four hours no CTGF signal 
could be detected. The time-dependent induction of CTGF was analysed densitometrically.Page 4 of 9
(page number not for citation purposes)
Comparative Hepatology 2007, 6:5 http://www.comparative-hepatology.com/content/6/1/5luciferase reporter consisting of nine CAGA-elements
from PAI-1 promoter, it significantly enhanced TGF-β-
induced PAI-1 in hepatocytes. Similar to our findings in
hepatocytes, Ma and coworkers found an increase of TGF-
β-induced PAI-1 expression through dexamethasone in
HTR-8 SV neo cells [33]. They suggested that dexametha-
sone enhancement on TGF-β-mediated PAI-1 expression
is not subjected to a direct transcriptional mechanism, but
rather through an additional protein. A successful TGF-β-
induced PAI-1 expression seems to be a positive coopera-
tion between the Smads and activator protein-1 (AP-1)
[30]. The AP-1 activity is supposed to be a result of a
directly TGF-β-induced MAPK signalling. Depending on
the composition of AP-1 (Jun-Fos, Jun-Jun or Jun-ATF2) a
positive or negative interaction with GR is possible
[34,35]. But we observed that an inhibition of c-Jun phos-
phorylation did not affect PAI-1 expression in hepato-
cytes. The inhibition of Mek-Erk interaction clearly
suppressed TGF-induced PAI-1, which points to coopera-
tive signalling between TGF-β and Erk-pathway for regu-
lating PAI-1 expression. In agreement with other groups
[31,36], we observed a low PAI-1 level in primary hepato-
cytes, but when PAI-1 was induced it was directly secreted.
Of particular concern is the fact that a costimulation with
both, TGF-β and dexamethasone, also strongly induce the
profibrogenic CTGF protein expression in hepatocytes. In
fibroblasts TGF-β-induced CTGF is enhanced by Ras/Mek/
Erk signalling and suppressed by JNK signalling and it
seems that Ras/Mek/Erk did not affect the Smad pathway
Effect of dexamethasone on a TGF-β-Smad 3-sensitive reporter construct [(CAGA)9- MLP-luc]Figure 3
Effect of dexamethasone on a TGF-β-Smad 3-sensitive reporter construct [(CAGA)9- MLP-luc]. (A) Dexametha-
sone inhibits TGF-β-Smad 3-signalling in Hep-G2. Hep-G2 was transfected with (CAGA)9- MLP-luc and stimulated with 1 or 2 
ng of TGF-β1. Four hours after incubation with various dexamethasone concentrations, cells were lysed and luciferase 
reporter gene activity was measured. Results are presented as light units relative to untreated cells. The presented data is the 
mean ± SD of three independent experiments, each performed in duplicates. (B) TGF-β decreases GR signalling. Hep-G2 cells 
were co-transfected with GRE4E1b-luc and Smad 3 plasmid. TGF-β decreases and over-expressed Smad 3 abrogates GR signal-
ling. Luciferase activities were measured using the Victor 1420 Multilabel Counter Luminometer (Wallac, Germany).
A)
B)Page 5 of 9
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Effects of JNK inhibitor II and Erk inhibitor on TGF-β and dexamethasone induced CTGF expression in hepatocytesFigure 4
Effects of JNK inhibitor II and Erk inhibitor on TGF-β and dexamethasone induced CTGF expression in hepato-
cytes. (A) Three-days old hepatocytes were serum-starved before stimulation. Cells were treated with or without inhibitor 
and then stimulated for three hours with TGF-β and dexamethasone as indicated and thereafter immediately lysed. Cell lysates 
have been subjected to electrophoresis and Western blot. Corresponding expression of β-actin is shown as loading control. 
(B) Densitometrically evaluation of independent cell preparations showed that CTGF expression was not changed in the pres-
ence of JNK inhibitor (n = 2; light-grey). In comparison to untreated cells (n = 3; white bars) the addition of Erk inhibitor 
clearly inhibited TGF-β/dexamethasone induced CTGF expression (n = 2; dark-grey). BLU (Boehringer light units). (C) Just as 
well, densitometric analysis of PAI-1 demonstrated that the Erk inhibitor repressed TGF-β and dexamethasone induced 
expression. (Native – n = 4; with Erk inhibitor – n = 2).
A)
B)
C)
Comparative Hepatology 2007, 6:5 http://www.comparative-hepatology.com/content/6/1/5[15]. In agreement with Leask et al. [15] we found that
TGF-β induction of CTGF is dependent on Erk-activity in
hepatocytes. In contrast to the fibroblasts an inhibition of
c-Jun phosphorylation through JNK did not change TGF-
β induced CTGF expression.
How can we explain the synergistic effect of dexametha-
sone and TGF-β on PAI-1 and CTGF expression in hepato-
cytes? On the one hand, glucocorticoid bound GR inhibits
a TGF-β-sensitive reporter signal and, vice versa, TGF-β
and/or ectopic Smad 3 expression decreased a glucocorti-
coid-sensitive luciferase reporter in Hep-G2. These results
indicate an antagonizing interaction between the TGF-β-
Smad and the glucocorticoid pathway, e.g. via the pro-
posed GR-Smad 3 protein-protein interaction [37,38].
However, the dexamethasone enhancement of TGF-β up-
regulated CTGF could be antagonized by mifepristone,
which argue for a GR-dependent synergistic effect in pri-
mary hepatocytes. On the other hand, it is conceivable
that cell type-specific co-regulators directed the hormonal
response by preventing a GR-Smad interaction and facili-
tating a subsequent DNA binding. We suppose that the
TGF-β mediated induction of CTGF or PAI-1 expression
needs the Smad pathway as well as the Ras-Mek-Erk-path-
way (Fig. 5). In fact, our data demonstrate that a simulta-
neous stimulation with TGF-β and dexamethasone leads
to a "super induction" of PAI-1 and CTGF in hepatocytes,
which argue for synergistic transcriptional gene activation
and against a direct GR-Smad 3 crosstalk. Additionally,
our results raise the intriguing possibility that CTGF
requires a factor, which is permissive for a real-time secre-
tion by the cells. Overall, our results provide new evidence
that in hepatocytes CTGF is regulated via the TGF-β-Smad
3- and the TGF-β-Ras-Mek-Erk- as well as the GR-pathway.
Conclusion
In summary, our results clearly showed a synergistic effect
of dexamethasone on TGF-β-induced PAI-1 and CTGF
expression in primary hepatocytes, which can be selec-
tively inhibited by supressing the Mek-Erk activity. The
differential secretion of PAI-1 and CTGF is suggested to be
relevant in organized extracellular matrix deposition and
thus in liver cell interaction.
Diagram of the proposed role of Erk-pathway in the control of CTGF and PAI-1 expressionFigure 5
Diagram of the proposed role of Erk-pathway in the 
control of CTGF and PAI-1 expression. CTGF and PAI-
1 seems to be regulated by two TGF-β-induced pathways: 
TGF-β-Smad 3 and TGF-β-Ras-Mek-Erk pathway. Addition-
ally, dexamethasone clearly induced CTGF expression but it 
did not affect PAI-1 expression in hepatocytes. [TGF-β] trans-
forming growth factor beta, [Smad 3] mothers against DPP 
homolog 3, transcription factor, [Ras] rat sarcoma, proto-
oncogen, [Mek] MAP-Erk-Kinasen; [Erk] Extra-cellular-signal 
regulated Kinase; [dexamethasone] glucocorticoid, transcrip-
tion factor; [JNK] c-Jun N-terminale Kinase; [Erk i] Erk inhibi-
tor binds selectively to Erk2 and prevent its interaction with 
Mek.
Table 1: Synopsis of the predicted TGF-β and GR response elements in PAI-1 and CTGF promoter sequences
Gene Promoter motifs Pathway Promoter sequence Ref.
hCTGF GTGTCAAGGGGTCAGGAT TGF-β inducible -162 to 128 [14]
hCTGF GAGGAATGCGAGGAATG TGF-β-Smad3/4 -805 to +17 [15]
hCTGF - GR -292 to +22 [25]
mCTGF No direct binding, interaction with other TF (STAT3?) GR -897 to -628 (mouse strain specific) [19]
hPAI-1 AG(C/A)CAGACA TGF-β-Smad3/4 -730, -580, -280 [26]
hPAI-1 AG(C/A)CAGACA TGF-β-Smad3/4 -732 to -721 [27]
PAI-1 MLP(CAGA)9-luc TGF-β-Smad3/4 Reporter plasmid [28]
hPAI-1 - GR -800, -549, -100, +75, [17]
rPAI-1 AGCACACACTGTTCT GR -1212 to -1196 [29]
Besides the transcriptional activation of gene expression through potentially response elements of single transcription factors, and apart from a cell-
type specific composition of those transcription factors, a superior regulation is conceivable, e.g. a diversity in methylation sites or the condensation 
status of the chromatin. GTCTAGAC: TGF-β-Smad3/4 consensus sequence; GGTACANNNTGTTCT: GR consensus sequence; r: rat; h: human; 
m: mouse.Page 7 of 9
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Materials
Dexamethasone was obtained from Sigma (Taufkirchen,
Germany). Recombinant human TGF-β1 was obtained
from R&D systems (Minneapolis, MN). Erk activator
inhibitor protein (328000) and JNK inhibitor II (420119)
were purchased from Calbiochem.
Cell isolation and culture
Hepatocytes were isolated from Sprague-Dawley rats (250
g) as described by Seglen [39], seeded with a density of 5
× 106 cells/cm2 and cultured in Dulbecco's modified
Eagle's medium (DMEM, Bio-Whittaker Europe, Verviers,
Belgium), supplemented with 4 mmol/l L-glutamine, 10
% FCS, and penicillin (100 IU/ml)/streptomycin (100 μg/
ml). All cultures were maintained at 37°C, 5 % CO2/95 %
air in a humidified atmosphere. HepG2 cells [40] were
cultured in supplemented DMEM described above. Hepa-
tocytes were treated with cytokines and/or hormones
under serum free conditions. The inhibitors (Erk inh. 0.2
μM, JNK inh. 10 μM) were pre-incubated about 10 to 30
minutes before dexamethasone or TGF-β stimulation.
Lactate dehydrogenase assay (LDH)
Lactate dehydrogenase activity was assayed using the IFCC
method (International Federation of Clinical Chemistry
and Laboratory Medicine), at 37°C, in the media of hepa-
tocytes treated with TGF-β and dexamethasone as indi-
cated. The culture media were harvested and LDH was
measured with Roche P800 modular (Roche Diagnostics
GmbH, Germany).
Western blotting
Freshly isolated hepatocytes were seeded in 90 mm2 cul-
ture dishes at a density of 5.0 × 106 cells. Directly after
serum starvation, cells were exposed for TGF-β, dexameth-
asone or both as indicated. Thereafter, cells were har-
vested and the protein concentration was determined by
MicroBC assay protein quantification kit (Interchim,
Montluçon, France). Equal amounts of protein (40 μg)
were separated in a 4–12 % Bis-Tris NuPAGE gel (Invitro-
gen) and transferred to a 0.45 μm nitrocellulose mem-
brane (AppliChem, Darmstadt, Germany). Blots were
washed and blocked with 5 % milk/TBST over night at
4°C. Primary antibodies: PAI-1 (Abcam, Cambridge, UK),
CTGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
β-actin (Sigma); Phospho-p44/42 MAP kinase (Erk1/
Erk2; 9101s) and p44/42 MAP kinase (9102) were pur-
chased from Cell Signalling. The phospho-p44/42 MAP
kinase antibody detects endogenous level of phosphor-
ylated Thr202/Tyr204 of Erk1 and Thr183/Tyr185 of rat
Erk2. The first antibody was incubated 2 h at RT and the
second antibody (HRP conjugated; Santa Cruz) was incu-
bated for 1 h at RT, respectively, both diluted in 2.5 %
milk/TBST. Blots were developed with SuperSignal West
Dura (Pierce, Bonn, Germany). Densitometric analysis
has been carried out with Lumi Imager (Boehringer Man-
nheim; software version 3.0). Significance of differences
was established by the paired Student's t-test.
Transfection and luciferase assay
Hep-G2 cells were seeded in 12- or 24-well plates at a den-
sity of 3.0 - 2.5 × 104 cells/well. To measure TGF-β signal-
ling the TGF-β- sensitive reporter construct, (CAGA)9 -
MLP-luc [26] was transiently transfected by using FuGENE
6 (Roche). GR-signalling was measured by using the
GRE4E1b-luc reporter, kindly provided by Gelehrter (Uni-
versity of Michigan, USA; [37]). Smad 3 plasmid was
kindly provided by S. Dooley (University Mannheim, Ger-
many), respectively.
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